OTC Markets OTCPK - Delayed Quote USD

Genscript Biotech Corporation (GNNSF)

1.3550

0.0000

(0.00%)

At close: January 29 at 3:00:00 PM EST

GenScript's 2025 JPM Global Forum Concludes Successfully in San Francisco

GenScript Biotech, a global biotechnology leader in life science, biologics manufacturing, synthetic biology, and cell therapies announced the successful conclusion of its 2025 JPM Global Forum held on January 15 in San Francisco. The event, themed "Challenges and Opportunities of Cell and Gene Therapy in the New Era," attracted more than 700 attendees both in person and via live-stream, featuring a series of keynote speeches and panel discussions that offered insights into the future of cell an

PR Newswire 9 days ago

GNNSF
0.00%
3 Leading Stocks Estimated To Be Up To 49.3% Below Their Intrinsic Value

In the current global market landscape, cooling inflation in the U.S. and robust bank earnings have driven major stock indexes higher, with value stocks outperforming growth shares significantly. Amid these developments, identifying undervalued stocks becomes crucial as they offer potential opportunities for investors looking to capitalize on discrepancies between market prices and intrinsic values.

Simply Wall St. 10 days ago

GNNSF
0.00%
FITGF

ASMVF
3 Stocks That May Be Undervalued In December 2024

As global markets navigate a period of cautious optimism following the Federal Reserve's recent rate cut and ongoing political uncertainties, investors are closely watching for opportunities amid fluctuating indices. With U.S. stocks experiencing broad-based declines and European markets facing challenges from potential trade tariffs, the search for undervalued stocks becomes particularly relevant in this climate. Identifying potentially undervalued stocks requires careful consideration of a...

Simply Wall St. last month

GNNSF
0.00%
GenScript Announces 4th Annual Biotech Global Forum in San Francisco

GenScript Biotech, a global biotechnology leader in life sciences, biologics manufacturing, synthetic biology, and cell therapies is proud to announce its 4th Annual Biotech Global Forum, scheduled for January 15, 2025, at the San Francisco Marriott Marquis.

PR Newswire last month

GNNSF
0.00%
Transforming Plasmid DNA Purification: Automation That Delivers Optimal Yields and Low Endotoxin

GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its Life Sciences subsidiary, GenScript, has launched a next generation DNA purification platform: The AmMag™ Quatro Mini-1100. This new instrument complements the widely acclaimed AmMag Quatro Maxi-1400, providing comprehensive solutions for both mini- and maxi-scale plasmid purification.

PR Newswire last month

GNNSF
0.00%
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development

GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech Global Forum in London, UK. Since its inaugural session at the J.P. Morgan Healthcare Conference in San Francisco in 2020, the forum has become a significant platform for advancing cell and gene therapy (CGT). This year's move to Europe underscores GenScript's commitment to driving the global CGT innovation and fostering international col

PR Newswire 2 months ago

GNNSF
0.00%
GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer

GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova Medicines, which recently entered into an agreement with Merck to advance treatment.

PR Newswire 2 months ago

GNNSF
0.00%
Seasoned Marketing Executive Joins GenScript as Chief Marketing Officer

GenScript Biotech, a global leader in biotechnology leveraging advanced, proprietary gene synthesis and life-science technologies, announced today that Mrs. Aylin Kosova Bilgin has joined as the first-ever Chief Marketing Officer for GenScript Life Science Group.

PR Newswire 2 months ago

GNNSF
0.00%
GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia

GenScript Biotech Corporation ("GenScript"), a global leader in life sciences services and products, has announced the establishment of new operations site and logistics center in Sydney, Australia. This strategic expansion represents a significant milestone in GenScript's continued commitment to supporting the rapid growth of the biotechnology sector in Australia. It also underscores the company's determination to strengthen GenScript's presence in the Asia-Pacific region and globally, advancin

PR Newswire 2 months ago

GNNSF
0.00%
Genscript Biotech Corp (GNNSF) (H1 2024) Earnings Call Highlights: Robust Revenue Growth Amidst ...

Genscript Biotech Corp (GNNSF) reports a 43.5% revenue increase, narrowing net losses, and strong performance in Legend, despite ProBio setbacks and geopolitical tensions.

GuruFocus.com 3 months ago

GNNSF
0.00%
GenScript Appoints New Board Members to Drive Global Growth

GenScript Biotech Corporation ("GenScript"), a global leader in life sciences products and services, announced the appointment of Dr. Ross Allen Grossman as a Non-Executive Director and Dr. Alphonse Galdes as an Independent Non-Executive Director. These appointments not only further diversify the Group's Board but also highlight GenScript's commitment to building an international, diverse, and highly specialized corporate governance team. With the addition of these two directors, the company is

PR Newswire 4 months ago

GNNSF
0.00%
GenScript Biotech Reports First Half 2024 Results

GenScript Biotech Corporation (HKEX: 1548.HK), a leading global technology and service provider of life science R&D and manufacture, today reported its first half 2024 financial results for the six months ended June 30, showcasing impressive revenue growth, significant improvements in gross profit, and strategic advances across its business segments. GenScript is also deepening its commitment to environmental, social, and governance (ESG) practices, marking a significant step towards sustainable

PR Newswire 5 months ago

GNNSF
0.00%
Genscript Biotech Leads Trio Of Value Stocks On SEHK Estimated Below Market Valuations

As global markets navigate through mixed economic signals and varied regional performances, the Hong Kong market has shown resilience amidst broader Asian market challenges. This context sets a compelling stage for investors to consider undervalued stocks, such as Genscript Biotech, which may present opportunities in an environment where discerning value is key.

Simply Wall St. 5 months ago

GNNSF
0.00%
BSDGF

BSDGY
Exploring Undervalued SEHK Stocks With Intrinsic Discounts Ranging From 41.1% To 48.9%

Amidst a mixed landscape for global markets, Hong Kong's Hang Seng Index has shown resilience with a modest gain of 0.46% in a holiday-shortened week, reflecting nuanced investor sentiment towards the region's economic outlook. In such an environment, identifying undervalued stocks can be particularly compelling as they may represent opportunities for investors seeking value in a market characterized by cautious optimism and uneven economic indicators.

Simply Wall St. 6 months ago

1209.HK

GNNSF
0.00%
BAIGF
Exploring Undervalued Opportunities: 3 SEHK Stocks With Intrinsic Discounts Ranging From 27.6% To 41.4%

Amidst a backdrop of fluctuating global markets, the Hong Kong stock market presents intriguing opportunities, evidenced by its recent modest gains. As investors seek value in a landscape marked by mixed economic signals, identifying undervalued stocks becomes a prudent strategy to explore potential growth avenues.

Simply Wall St. 7 months ago

BAIGF

IGGGF

GNNSF
0.00%
GenScript Hosts Inaugural APAC Distributor Meeting, Strengthening Regional Partnerships for Scientific Advancements

GenScript, the world-leading biotechnology company specializing in life science research and applications, hosted the inaugural Asia-Pacific (APAC) Distributor Meeting in Nanjing, China. The event, which took place from 3rd to 6th June, brought together distributors from across the APAC region to discuss strategies, share insights, and strengthen collaborations to better serve the scientific community.

PR Newswire 7 months ago

GNNSF
0.00%
GenScript Biotech Corporation Launches FLASH Gene Service: The Fastest and Most Affordable Gene Synthesis Solution on the Market

GenScript Biotech Corporation, renowned for its relentless innovation in synthetic biology and industry-leading gene synthesis services, is excited to announce the launch of its newest offering, GenScript FLASH Gene service, the ultra-fast sequence-to-plasmid (S2P) service. This flagship offering addresses the urgent demand for delivering gene constructs with unmatched speed, quality, and cost-efficiency.

PR Newswire 7 months ago

GNNSF
0.00%
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

GenScript Biotech Corporation, a global leader in life science research tools and services, has today announced the expansion of its in vitro transcription (IVT) RNA synthesis portfolio to include self-amplifying RNA (saRNA). This cutting-edge addition reinforces GenScript's position at the forefront of IVT RNA technology, offering a new and novel format for researchers working in applications such as vaccine, cancer immunotherapy, and gene or cell therapy development.

PR Newswire 8 months ago

GNNSF
0.00%
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing

SAN FRANCISCO, April 25, 2024--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation (GenScript), one of the world's leading providers of life-science research tools and services, today announced a strategic partnership around the automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process.

Business Wire 9 months ago

GNNSF
0.00%
GenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint

Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 Environmental, Social, and Governance (ESG) report. This report showcases the company's dedicated efforts in ESG governance, corporate social responsibility fulfillment, and environmental conservation practices. It underscores GenScript's unwavering commitment to advancing green initiatives and seamlessly integrating sustainable development strate

PR Newswire 9 months ago

GNNSF
0.00%

Performance Overview

Return	GNNSF	HANG SENG INDEX
YTD	+20.98%	+0.92%
1-Year	-34.54%	+26.79%
3-Year	-55.93%	-14.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Genscript Biotech Corporation (GNNSF)

GenScript's 2025 JPM Global Forum Concludes Successfully in San Francisco

3 Leading Stocks Estimated To Be Up To 49.3% Below Their Intrinsic Value

3 Stocks That May Be Undervalued In December 2024

GenScript Announces 4th Annual Biotech Global Forum in San Francisco

Transforming Plasmid DNA Purification: Automation That Delivers Optimal Yields and Low Endotoxin

The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development

GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer

Seasoned Marketing Executive Joins GenScript as Chief Marketing Officer

GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia

Genscript Biotech Corp (GNNSF) (H1 2024) Earnings Call Highlights: Robust Revenue Growth Amidst ...

GenScript Appoints New Board Members to Drive Global Growth

GenScript Biotech Reports First Half 2024 Results

Genscript Biotech Leads Trio Of Value Stocks On SEHK Estimated Below Market Valuations

Exploring Undervalued SEHK Stocks With Intrinsic Discounts Ranging From 41.1% To 48.9%

Exploring Undervalued Opportunities: 3 SEHK Stocks With Intrinsic Discounts Ranging From 27.6% To 41.4%

GenScript Hosts Inaugural APAC Distributor Meeting, Strengthening Regional Partnerships for Scientific Advancements

GenScript Biotech Corporation Launches FLASH Gene Service: The Fastest and Most Affordable Gene Synthesis Solution on the Market

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Multiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing

GenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint

Performance Overview